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Summary: A number of acetoxy-substituted dibenzo[a,g]quinolizin-8-ones were 
synthesized by the reaction of 1-oxoisoquinolines with substituted homophthalic acid 
anhydride. A l l of the derivatives with acetoxy groups in positions 3 and 10 bind to the 
estrogen receptor. Relative binding affinities (RBA) ranged from 1.8 to 5.6 (estradiol: 
R B A = 100) when the substituent at C-6 was a short alkyl group. Introduction of 
additional oxygen functions in the 2- and/or 11-position decreased binding affinities. 
Analyses of the enantiomers of 6-methyl (6b) and 6-ethyl (6c) derivatives revealed that 
the receptor binding is mainly due to one optical isomer (e.g. (-)-6b, 9.9; (+)-6b, 0.6). 
In hormone-sensitive human MCF-7 breast cancer cells, compounds with one acetoxy 
group in each aromatic ring strongly inhibited cellular growth. Despite marked differ-
ences in receptor affinity, the enantiomers displayed similar activities in this cell 
culture. In hormone-independent M D A - M B 231 mammary tumor cells, only a weak 
cytostatic effect was recorded at 10"5 M. In the immature mouse uterine weight test, 
minimal estrogenic activity was observed. At higher doses, a significant anti-estrogenic 
effect became evident. It is assumed that the estrogen antagonism is responsible for 
the specific cytostatic effect in MCF-7 breast cancer cells. 
Key words: cytostatic activity/dibenzo[a,g]quinolizin-8-ones/estrogen receptor 
affinity/synthesis 
Introduction 
Endocrine therapy of hormone-dependent breast cancer has proved to be a valuable 
alternative to the treatment with cytostatic drugs which usually lack specificity for tumor 
cells. The drugs presently in use for this indication display only a rather limited spectrum 
of activity. Among the patients with estrogen receptor-positive mammary carcinoma, 
~40% do not respond to the treatment with tamoxifen which is still the antiestrogen of 
choice (Harmsen & Porsius, 1988). Our approach to improve the activity of drugs acting 
via the estrogen receptor is based on structural modifications of compounds with 
inherent cytostatic potency. 
In a previous paper (Ambros et al., 1990), we reported on the biological activities of a 
number of indolo[2,l-a]isoquinolines. We extended these studies to other tetracyclic 
systems containing two fused six-membered rings with a nitrogen as bridge head atom 
(Weimar et al., 1991a,b). One of these structures is dibenzo[a,g]quinolizine which is 
closely related to the berbine alkaloids (Zee-Cheng & Cheng, 1973). This class of natural 
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products is known to possess cytostatic activity, especially if the compounds contain a 
quaternary nitrogen atom (Cushman et al., 1979). For high binding affinity for the 
estrogen receptor, it is necessary to avoid structural elements with a basic character in 
the center of the molecule (von Angerer et al., 1982). Therefore, we introduced a 
carbonyl group next to the nitrogen atom. In this study, a number of 
dibenzo[a,g]quinolizin-8-ones with acetoxy groups in different positions of the aromatic 
rings and short alkyl chains at C-6 (Chart 1) were synthesized and tested for their 
estrogen receptor affinities, their cytostatic activities and their endocrine properties. 
t>COCH3 
R 1 t R3 = h , O C O C H 3 
R 2 = C H 3 , C 2 H 5 , C 3 H 7 
Chart 1 
Materials and methods 
Melting points (m.p.) were determined on a Büchi 510 apparatus and are uncorrected. 
Elemental analyses were performed by the Mikroanalytisches Laboratorium, University 
of Regensburg. 1 H - N M R spectra were obtained on a Varian E M 390 and Bruker W M 
250 spectrometer, and are consistent with the assigned structures. The purity of all 
compounds used for tests was checked by H P L C . 
Reagents 
[2,4,6,7- 3H(N)]Estradiol (110 Ci/mmol) was obtained from New England Nuclear 
(Dreieich, F R G ) . Hormones and biochemicals were purchased from Sigma (München, 
F R G ) . T E A [Tris buffer (10 m M , p H 7.4) supplemented with E D T A (1.5 mM) and N a N 3 
(3 mM)] was used as buffer. 
General procedure for the synthesis of the 1,2,3,4-tetrahydro-methoxy-l-oxo-
isoquinolines 3b-f 
The respective ß-phenylethylamine 1 (100 mmol) was dissolved in dry C H 2 C 1 2 (50 ml) 
and N ( C 2 H 5 ) 3 (10.0 g). Ethyl chloroformate (10.8 g) in 50 ml of dry C H 2 C 1 2 was added 
and the mixture was stirred for 1 h. The precipitate was dissolved in 2 N H C l , stirred 
again and extracted with C H 2 C 1 2 . After washing of the organic layer with water and 
drying ( N a 2 S 0 4 ) , the solvent was evaporated. A l l compounds 2 were obtained as 
colorless oils and were used without further purification. Yields were nearly quantitative. 
Polyphosphoric acid (100 g) was preheated to 140°C (oil bath temperature). Com-
pound 2 was poured directly into the polyphosphoric acid and the mixture was kept at 
140°C for 1 h. After cooling, the mixture was suspended in ice water (100 ml). The 
solution was made alkaline and extracted with C H 2 C 1 2 (6 x 150 ml). The organic layer 
was dried ( N a 2 S 0 4 ) . After evaporation of the solvent, the residue was purified by 
chromatography ( S i 0 2 ; E t O A c ) to give colorless crystals. Yields and m.p. values are 
reported in Table I. 
Table I 1,2,3,4-Tetrahydro-methoxy-l-oxoisoquinolines 3 
o 
Compound R1 R2 % Yield Formula* m.p.h (°C) 
3ac H H 65 C 1 0 H 1 0 N O 2 137-138 
3b H C H 3 50 C n H 1 3 N 0 2 147 
3c H Q H 5 50 C 1 2 H 1 5 N 0 2 116 
3d H C 3 H 7 45 C 1 3 H 1 7 N 0 2 73 
3e O C H 3 C H 3 50 C 1 2 H 1 5 N 0 3 171 
3f O C H 3 C 2 H 5 50 C 1 3 H 1 7 N 0 3 151 
a Analyzed for C and H within ± 0 . 4 % of the calculated values 
b Recrystallized from E t 2 0 
c Umezawa et al. (1980) 
General procedure for the synthesis of the 5,6-dihydro-methoxy-8H-
dibenzo[a,g]quinolizine-8-ones 5b-i 
1-Oxoisoquinoline 3 (5 mmol) was suspended in chlorobenzene (15 ml), pyridine (0.4 
ml) and P O C l 3 (0.2 ml dissolved in 5 ml of chlorobenzene) were added. The suspension 
was stirred for 15 min at room temperature, then homophthalic acid anhydride 4a 
(Horeau & Jacques, 1948) or 4b (Potts & Robinson, 1955) was added. The mixture was 
stirred for 15 min, then refluxed for 1 h. After cooling, C H 2 C 1 2 (50 ml) was added. The 
organic layer was washed with 10% N a O H , dried ( N a 2 S 0 4 ) and the solvent was 
evaporated. The residue was chromatographed ( S i 0 2 ; E t O A c ) to afford colorless 
crystals. Yields and m.p. are reported in Table II. 
Compound 5a has been described previously (Weimar et al., 1991a). 
General procedure for the synthesis of acetoxy-5,6-dihydro-8H-dibenzo[a,g] 
quinolizine-8-ones 6b-i 
Methoxy-8-oxoberbine 5 (100 mg dissolved in 10 ml of dry C H 2 C 1 2 ) was added dropwise 
to B B r 3 (0.1 ml) in dry C H 2 C 1 2 (10 ml). The mixture was refluxed for 1 h and stirred at 
Table II 5,6-Dihydro-methoxy-8//-dibenzo[a,g]quinolizin-8-ones 5 
'OCH3 
Compound R1 R2 R3 % Yield Formula* m.p.b (°C) 
5ac H H H 60 C 1 9 H 1 7 N 0 3 176-177 
5b H C H 3 H 55 C 2 0 H 1 9 N O 3 138 
5c H C 2 H 5 H 55 C 2 1 H 2 1 N 0 3 140 
5d H C 3 H 7 H 40 C 2 2 H 2 3 N 0 3 134 
5e H C H 3 O C H 3 50 C 2 1 H 2 1 N 0 4 192-194 
5f H C 2 H 5 O C H 3 50 C 2 2 H 2 3 N 0 4 186-187 
5g O C H 3 C H 3 H 55 C 2 1 H 2 1 N 0 4 141 
5h O C H 3 C 2 H 5 H 55 C 2 2 H 2 3 N 0 4 154 
5i O C H 3 C 2 H 5 O C H 3 55 C 2 3 H 2 5 N 0 5 191 
a Analyzed for C and H within ± 0 . 4 % of the calculated values 
b Recrystallization from E t O H 
c Weimar et al. (1991a) 
room temperature for 12 h. With cooling, 10 ml of an aqueous solution of N a H C 0 3 was 
added. Then, E t O A c (25 ml) was added and the mixture was stirred for 15 min. The 
organic layer was separated and the aqueous phase was extracted with E t O A c . The 
combined organic layers were washed with saline and dried ( N a 2 S 0 4 ) . After the solvent 
was removed, the residue was dried in vacuo. A c 2 0 (6 ml) and pyridine (1 ml) were 
added, and the mixture was refluxed for 1 h. Excess of reagents was evaporated in vacuo. 
The remaining residue was washed with ether and chromatographed ( S i 0 2 ; E t O A c ) . 
Recrystallization from M e O H yielded 6 as colorless crystals. Yields and m.p. are re-
ported in Table III, and N M R data are given in Table I V . 
Compound 6a has been described previously (Weimar et al., 1991a). 
Chromatographic separation of the enantiomers of 6b and 6c 
The enantiomers of 6b and 6c were separated semipreparatively by liquid chroma-
tography on triacetylcellulose (20-30 jxm) (Koller et al, 1983) with E t O H as eluent at 
22°C (2-3 bar, flow rate 3-4 ml/min). Both racemates showed baseline separations with 
enantioselectivities of 2.2 and 2.0, respectively. The enantiomeric purities were close to 
100%. 
(-)-6b: k_ = 2.9, m.p. 113-115°C, [ a ] 5 4 6 = - 5 4 ° ± 6°, [ a ] 4 3 6 = +16° ± 4° in E t O H . 
(+)-6b: k + = 1.3, m.p. 96-98°C, [ a ] 5 4 6 = +50° ± 6°, [ a ] 4 3 6 = - 1 6 ° ± 4° in E t O H . 
(-)-6c: k_ = 2.3, m.p. 112-114°C, [ a ] 5 4 6 = - 3 3 ° ± 6°, [ a ] 4 3 6 = +80° ± 9° in E t O H . 
(+)-6c: k + = 1.2, m.p. 108-110°C, [ a ] 5 4 6 = +24° ± 5°, [ a ] 4 3 6 = - 8 0 ° ± 8° in E t O H . 
Table III Acetoxy-5,6-dihydro-8//-dibenzo[ö,g]quinolizine-8-ones 6 
Compound R1 R2 R3 % Yield Formula* m.p.b (°C) RBA 
6ad H H H 75 C 2 1 H 1 7 N 0 5 206-208 0.3 
6b H C H 3 H 65 C 2 2 H 1 9 N 0 5 179-181 5.6 
(+)-6b H C H 3 H - C 2 2 H 1 9 N 0 5 96-98 0.6 
(-)-6b H C H 3 H - C 2 2 H 1 9 N O s 113-115 9.9 
6c H C 2 H 5 H 65 C 2 3 H 2 1 N 0 5 164-166 2.8 
(+)-6c H C 2 H 5 H - C 2 3 H 2 1 N 0 5 108-110 0.7 
(~)-6c H C 2 H 5 H - C 2 3 H 2 1 N 0 5 112-114 5.8 
6d H C 3 H 7 H 55 C 2 4 H 2 3 N 0 5 124-125 1.8 
6e H C H 3 OCOCH3 65 C 2 4 H 2 1 N 0 7 214-216 0.8 
6f H C 2 H 5 OCOCH3 65 C 2 5 H 2 3 N 0 7 133-135 0.4 
6g O C O C H 3 C H 3 H 70 C 2 4 H 2 1 N 0 7 215-216 0.6 
6h OCOCH3 C 2 H 5 H 70 C 2 5 H 2 3 N 0 7 159-160 0.5 
6i OCOCH3 Q H 5 OCOCH3 60 C 2 7 H 2 5 N 0 9 154-155 0.1 
a Analyzed for C and H within ± 0 . 4 % of the calculated values 
b Recrystallization of the racemates from M e O H 
c Relative binding affinity for the calf uterine estrogen receptor is the ratio of the molar concentration of 17ß-
estradiol (E2) and inhibitor required to decrease the amount of bound [3H]E2 by 50%, x 100 
d Weimar et al. (1991a) 
Estradiol receptor binding assay 
Fresh calf uteri, stored in ice-cold saline, were freed of adherent fat and connective tissue 
at 4°C. After the addition of T E A buffer (1 ml/g), the uteri were homogenized by 
treatment with an ultraturrax mixer ( I K A , F R G ) and a glass-in-glass homogenizer 
(Potter S; Braun, F R G ) at 4°C. Lipids were separated by centrifugation at 700 g and 
discarded. The homogenate was centrifuged at 105 000 g for 100 min (0°C). The super-
natant (cytosol) was then used for determining the affinity of compounds for the estrogen 
receptor. The protein concentration of the cytosol was ~15 mg/ml, leading to a final 
concentration of 3 mg/ml in the assay. 
For the determination of the relative binding affinity ( R B A ) , the described procedure 
was applied with modifications (von Angerer et al., 1984). The 500 |JL1 incubation mixture 
comprised 5 n M [ 3H]17ß-estradiol (added in 100 JULI T E A ) , 10" 9 -10" 5 M competing ligand 
(in 100 |xl T E A ) , 100 |xl of uterine cytosol and T E A . The mixture was incubated for 18 h 
at 4°C, 0.5 ml of dextran-coated charcoal ( D C C ) slurry (0.8% charcoal Norit A and 
0.008% dextran in T E A ) was added to the tubes and the contents were mixed. The tubes 
were incubated for 90 min at 4°C and then centrifuged at 700 g for 10 min to pellet the 
charcoal. A n aliquot (100 \xA) of the supernatant was removed and the radioactivity was 
Table IV ^ - N M R data of acetoxy-6-alkyl-5,6-dihydro-8/f-dibenzo[a,g]quinolizin-8-ones 6b-i 
Compound 8 [p.p.m.] (recorded in CDCl3 with TMS as internal standard) 
6b 1.13 (d,/ = 7Hz;3H,-CH 3), 2.30 (s;6H,-CO-CH 3), 2.63-3.38 (m;2H,-CH 2-), 
5.45-5.77 (m;lH,-CH-), 6.87-7.90 (m;6H,ArH,VinylH), 8.12 (d,/ = 2.5Hz; 
l H , A r H ) 
6c 0.88 (t,/ = 7.5Hz;3H,-CH 3), 1.20-1.75 (m;2H,-C// 2-CH 3), 2.33 (s;6H,-CO-
CH 3 ) , 2.93-3.52 (m;2H,-CH 2-), 5,18-5.63 (m;lH,-CH-), 6.92-7.93 
(m;6H,ArH,VinylH), 8.10 (d,/ = 2.5Hz;lH,ArH) 
6d 0.85 (t,/ = 7.25Hz;3H,-CH 3), 1.26-1.55 (m;4H,-C// 2 -C// 2 -CH 3 ) , 2.33 (s;3H,-
CO-CH 3 ) , 2.35 (s;3H,-CO-CH 3), 2.96 ( A B X , 2 / A B = 16Hz, 3 / B X = 5.5Hz;lH,-
CH-/ / ) , 3.15 ( A B X , 2JAB = 16Hz , 3 / A X = 2Hz;lH,-C//-H), 5.46-5.55 (m;lH,-
CH-), 6.98 (s;lH,VinylH), 7.02 (d,/ = 2.5Hz;lH,ArH), 7.11 (dd,^ 2 =. 9/2.5Hz; 
l H , A r H ) , 7.39 (dd,/ 1 / 2 = 9/2.5Hz;lH,ArH), 7.58 (d,/ = 9Hz; lH,ArH), 7.82 
(d,/ = 9Hz; lH,ArH) , 8.11 (d,/ = 2.5Hz;lH,ArH) 
6e 1.18 (d,/ = 7Hz;3H,-CH 3), 2.35 (s;9H,-CO-CH 3), 2.61-3.62 (m;2H,-CH 2-), 
5.48-5.79 (m;lH,-CH-), 6.93-7.94 (m;5H,ArH,VinylH), 8.23 (s;lH,ArH) 
6f 0.88 (t,/ = 7.5Hz;3H,-CH 3), 1.13-1.75 (m;2H,-Cf/ 2-CH 3), 2.30 (s;9H,-CO-
CH 3 ) , 3.03 (t,/ = 3Hz;2H,-CH 2-), 5.22-5.53 (m;lH,-CH-), 6.82-7.93 
(m;5H,ArH,VinylH), 8.23 (s;lH,ArH) 
6g 1.18 (d,/ = 6Hz;3H,-CH 3), 2.34 (s;9H,-CO-CH 3), 2.80 ( A B X , 2 / A B = 16Hz, 3 / B X 
= 2Hz;lH,-CH-/f) , 3.07 ( A B X , 2 / A B ^ 16Hz, 3 / A X = 6Hz;lH,-C//-H), 5.40-
5.80 (m;lH,-CH-), 6.93 (s;lH,VinylH), 7.12 (s; lH,ArH), 7.39-7.62 
(m;3H,ArH), 8.10 (d,/ = 2Hz;lH,ArH) 
6h 0.88 (t^ = 7.5Hz;3H,-CH 3), 1.20-1.73 (m;2H,-C/ / r CH 3 ) , 2.31 (s;9H,-CO-
CH 3 ) , 3.05 (m;2H,-CH 2-), 5.22-5.56 (m;lH,-CH-), 6.93 (s;lH,VinylH), 7.13 
(s ; lH,ArH), 7.45 (dd,/ 1 / 2 = 9/2Hz;lH,ArH), 7.56 (s; lH,ArH), 7.68 
(s ; lH,ArH), 8.12 (dj = 2Hz; lH,ArH) 
6i 0.89 (t,/ = 7.5Hz;3H,-GH 3), 1.34-1.64 (m;2H,-C// 2-CH 3), 2.32 (s;3H,-CO-
CH 3 ) , 2.34 (s;9H,-CO-CH 3), 2.95-3.15 (m;2H,-CH 2-), 5.35-5.42 (m;lH,-CH-), 
6.87,7.12, 7.41,7.62,8.20 (5 x s;5H,ArH,VinylH) 
determined by liquid scintillation measurement after the addition of 2 ml of Quickszint 
212 (Zinsser). Non-specific binding was calculated using 4 | X M 17ß-estradiol as compet-
ing ligand. Six concentrations of competitor (1, 2, 5 and 10 x 10" 9 to 10 - 6 ) were chosen 
to provide values between 10 and 90% of specifically bound radioactivity. Radioactivity 
was plotted as a function of log concentration of competing ligand in the assay. The 
R B A was calculated as the ratio of the molar concentrations of estradiol and test 
compound required to decrease the amount of bound radioactivity by 50%, multiplied 
by 100. 
In vitro determination of cytostatic activity 
Hormone-sensitive human M C F - 7 breast cancer cells were obtained from the American 
Type Culture Collection (Rockvillej M D ) . Cells were grown in improved Minimal 
Essential Medium ( M E M ) , as modified by Richter et al. (1972) (Biochrom, Berl in, 
F R G ) , supplemented with glutamine (0.3 g/1), gentamycin (60 mg/1) and 5% newborn 
calf serum (NCS) (Gibco) or charcoal-treated N C C (CCS). C C S was prepared by 
incubation of 500 ml N C S with a dextran-coated charcoal pellet (Scholl et al., 1983) for 
4 h in a shaker at 0 -4°C . The procedure was repeated with a fresh pellet. After each 
incubation, the charcoal was removed by centrifugation. The serum was sterilized 
through a 0.20 |xm filter (Sartorius, Gött ingen, F R G ) and stored at - 2 0 ° C . A l l of the 
experiments were performed in the presence of phenol red. 
Cells were grown in a humidified incubator in 5% C 0 2 at 37°C. Two weeks before the 
start of the experiment, cells were switched from N C S to C C S and received two 
additional media changes before they were harvested with 0.05% trypsin-0.02% E D T A 
in 0.15 M N a C l . 
A t the start of the experiment, the cell suspension was transferred to 96-well micro titer 
plates (100 fxl/well). After growing them for 2-3 days in a humidified incubator with 5% 
C 0 2 at 37°C, the medium was replaced by one containing the drug. Control wells (16/ 
plate) contained 0.1% of ethanol that was used for the preparation of the stock solution. 
The initial cell density was determined by the addition of vinblastin (10~7 M ) . After 
incubation for 3 days, medium was removed and 100 |xl of glutaric aldehyde in PBS (1%) 
was added for fixation. After 15 min, the solution of aldehyde was decanted. Cells were 
stained by treating them for 25 min with 100 (xl of an aqueous solution of crystal violet 
(0.02%). After decanting, cells were washed several times with water to remove 
adherent dye. After the addition of 100 u-1 of ethanol (70%), plates were gently shaken 
for 1 h. The optical density of each well was measured in a microplate autoreader E L 309 
(Bio-tek) at 578 nm. Data calculation and analysis were performed on an Olivetti M24 
P C (Reile etat., 1990). 
Hormone-independent M D A - M B 231 human mammary tumor cells were obtained 
from the American Type Culture Collection. Cells were grown in McCoy 5a medium 
(Boehringer Mannheim, F R G ) supplemented with 10% N C S and gentamycin (40 |xg/ 
ml). Cytostatic activity was determined in a microtiter plate assay as described for M C F -
7 cells, with one exception: the incubation period was 6 days. 
Immature mice uterine weight tests 
Immature female mice (20 days old, of the N M R I strain) from Charles River Wiga 
(Sulzfeld, F R G ) were randomly divided into groups of 6-10 animals. To determine 
estrogenic activity, compounds were dissolved in polyethylene glycol/0.9% saline (7:3; 
100 |xl/animal) and injected subcutaneously on three consecutive days. Control animals 
received the vehicle alone. Twenty-four hours after the last injection, the animals were 
killed by cervical dislocation and weighed. Uteri were dissected free of fat and fixed in 
Bouin solution (saturated aqueous picric acid-40% formaldehyde-glacial acetic acid, 
15:5:1 by vol.) for 2 h. Uteri were freed from connective tissue, washed with a saturated 
alcoholic solution of L i C l , dried at 100°C for 24 h and weighed. The relative uterus 
weight was calculated by the formula: uterine dry weight (mg)/body weight (g), multi-
plied by 100. 
To determine the antiestrogenic activity, injections contained a standard dose (0.4 |xg) 
of estrone and increasing doses of the compounds. The inhibition (%) of the estrone-
stimulated uterine growth was estimated by the formula: 
100 - [ ( W S , T " WV)/(WS - W v ) X 100] 
where W S , T = relative uterus weight of animals treated with estrone standard (0.4 |xg) + 
test compound, Ww = relative uterus weight of control animals and W s = relative uterus 
weight of animals treated with estrone standard. 
Results 
Chemistry 
For the synthesis of the methoxy-substituted 8//-dibenzo[«,g]quinolizin-8-ones 5b-i, 
the corresponding 1,2,3,4-tetrahydro-l-oxo-isoquinolines 3b-f were used as starting 
materials. They were obtained by the reaction of the respective ß-phenylethylamine 1 
with ethyl chloroformate, followed by cyclization with polyphosphoric acid (Scheme 1). 
The 1-oxoisoquinolines 3 were reacted with the substituted homophthalic acid anhydride 
4a or 4b, according to the method described by Haimova et al. (1980), to afford the 
dibenzo[«,g]quinolizinones 5. After ether cleavage of 5, the free hydroxy derivatives 
were converted into the corresponding acetates 6 because the phenolic compounds are 
sensitive to autoxidation when exposed to air. A l l derivatives except 6a possess a chiral 
center in position 6. In order to study the influence of the steric arrangement at this 
particular carbon atom, we separated the enantiomers of 6b and 6c by liquid chroma-
tography on triacetyl cellulose (Koller et al., 1983) and characterized them (Table III). 
The assignment (+) and (—) for the enantiomers refers to the sign of optical rotation at 
546 nm. 
Biochemical and biological properties 
This study was primarily designed to develop agents for treating hormone-dependent 
mammary tumors. Since hormonal activity of an agent requires binding to the respective 
receptor, the binding affinities of acetoxy-substituted compounds for the estrogen 
receptor were determined. The affinities were measured in a competitive binding assay 
using [ 3 H]17ß-estradiol as tracer and calf uterine cytosol as receptor source (von Angerer 
et al., 1984). The D C C method was applied to remove unbound components of low 
molecular weight. The relative binding affinities ( % R B A ) are given as the ratio of the 
molar concentrations of 17ß-estradiol and dibenzoquinolizinone required to decrease the 
receptor-bound radioactivity by 50%, multiplied by 100. A s in previous studies (Ambros 
et al., 1990), the acetates were used for determination of the relative binding affinities for 
the estrogen receptors because the free hydroxy derivatives are unstable in solution and 
undergo oxidation by air. 
From preliminary studies, we knew that oxygen functions in positions 3 and 10 provide 
the best conditions for receptor binding (Weimar, 1990). Therefore, we kept this 
structural arrangement constant, varied the alkyl substituent at C-6, and introduced 
additional acetoxy groups into positions 2 and 11 because vicinal oxygen functions are 
known to enhance cytostatic activity in nitrogen-containing tetracycles (Ambros et al., 
1988). A s shown in Table III, a methyl or ethyl group at C-6 increased the binding 
affinity for the estrogen receptor, whereas catechol structures in one or both aromatic 
rings showed an opposite effect. The racemates with the highest binding affinities were 
separated into the enantiomers. There was a marked difference in binding affinity 
between (+)- and (-)-isomers. The R B A values of the (-)-forms exceeded that of the 
(+)-enantiomers by one order of magnitude. 
A l l of the acetoxy-substituted derivatives were tested for cytostatic activity against 
hormone-sensitive human M C F - 7 breast cancer cells. A t 10~5 M , all compounds except 6i 
with two catechol structures strongly inhibited cellular growth. A t 1 |uuvi, only derivatives 
with one oxygen function in each aromatic ring were very active. We also tested the 
enantiomers of 6b and 6c together with the racemates. Cytostatic activities of both 
stereoisomers and the racemic mixture of 6c were the same within the experimental 
error, despite the different binding affinities of (+)- and (-)-6c. With derivative 6b, a 

stronger cytostatic effect was observed for the (—)-enantiomer than for the (+)-isomer. 
This is in accord with the higher R B A value of the laevorotary form. 
In order to find out whether the cytostatic effect is receptor mediated or due to a 
general cytotoxic activity of this class of compounds, we determined the growth inhibi-
tory effect of the acetoxy-substituted dibenzoquinolizinones in hormone-independent 
human M D A - M B 231 mammary tumor cells (Table V ) . Only at the highest concentra-
tion (10~5 M ) was cytostatic activity recorded. Derivatives with catechol structures 
showed rather similar activities in both cell lines, making an unspecific mode of action 
likely. However, derivatives 6b, 6c and 6d, which possess high binding affinities for the 
estrogen receptor, already exerted a strong inhibitory effect in hormone-sensitive cells at 
a concentration of 10~6 M . Since 10-fold higher concentrations were required for an 
equivalent inhibition in hormone-independent cells, a mechanism mainly mediated by 
the estrogen receptor has to be assumed for these agents. 
For further studies, it was of interest whether these compounds act in vivo as estrogens 
or as antiestrogens. Therefore, we determined their endocrine profile in the mouse 
uterine weight test (Table V I ) . Estrogenic activity was generally very low. A weak 
uterotrophic effect was only observed at doses 1000-fold higher than that of estrone. A t 
these doses, however, most compounds gave rise to a significant antiestrogenic effect. 
With compounds 6c and 6d, the stimulation of uterine growth by estrone was inhibited by 
80%. In this assay, the (+)- and (-)-stereoisomers of 6b and 6c were tested too. A t a 
dose of 100 nmol/animal, only minor differences were found between the enantiomers 
concerning the uterotrophic effect. In the antiuterotrophic test, the (—)-isomers were 
more active than the (+)-enantiomers. Since the racemic mixtures were tested in experi-
ments different to those for the enantiomers, the values do not match exactly those of the 
enantiomers. 
Table V Effect of compounds 6a-i on the growth of MCF-7 and MDA-MB-231 mammary 
tumor cells 
Compound 1 x KT6 M 
% TIC 
MCF-7 
5 x 1(X~6 M 
% TIC 
1 X 10~5 M 
% TIC 
MDA-MB-23P 
1 X 10~5 M 
% TIC 
6a 57 ± 8 b 34 ± 7 b 21 ± 4 b 76 ± 5 b 
6b 54 ± 15b 35 ± 13b 10 ± 12b 52 ± 5 b 
(+)-6b 75 ± 20 52 ± 13 5 ± 10b 
(-)-6b 37 ± 16b 28 ± 12c 1 ± 10b 
6c 50 ± 22b 37 ± 17b 13 ± 10b 65 ± 6 b 
(+)-6c 44 ± 14c 41 ± 19b 7 ± 12b 
(~)-6c 61 ± 14 39 ± 17b 3 ± 3 b 
6d 54 ± 9 b 37 ± 8 b 25 ± 4 b 90 ± 4 b 
6e 80 ± 13b 85 ± 15° 70 ± l l b 41 ± 4 b 
6f 73 ± l l b 74 ± 12b 58 ± 10b 78 ± 9 b 
6g 87 ± 18 66 ± 13b 43 ± 9 b 37 ± 4 b 
6h 72 ± 13b 66 ± 10b 38 ± 8 b 55 ± 6 b 
61 96 ± 12 94 ± 17 87 ± 13c 43 ± 4 b 
Tamoxifen 52 ± 14b 31 ± 12b 7 ± l l b 
a Estrogen receptor-negative cells 
b Significant at P < 0.01 
c Significant at P < 0.05 
Table VI Estrogenic and antiestrogenic activity of 5,6-dihydroquinolizin-8//-dibenzo[ß,g]-8-
ones 6 in the mouse uterine weight test 
Antiuterotrophic test 
Uterotrophic test 
Compound Dose* [nmol] Relative uterus weight Relative uterus weightb,c Inhibition6 (%) 
Control 15.5 ± 2.3 15.5 ± 2.3 
Estrone 1.5 48.6 + 10.4 
6b 100 17.2 ± 4.8 38.8 ± 8.8 29.7e 
1000 23.5 + 3.5 33.6 + 12.4 45.3e 
6d 100 17.2 ± 4.3 44.7 ± 19.7 11.7 
1000 32.7 ± 6.8 22.1 ± 7.2 80.0f 
6f 100 16.3 ± 2.1 48.7 ± 13.1 
1000 16.7 ± 1.0 40.5 ± 9.6 24.4 
Control 14.9 ± 5.5 14.9 ± 5.5 
Estrone 1.5 43.5 ± 7.9 
6a 100 17.6 ± 1.9 43.5 ± 3.7 
1000 15.1 ± 2.0 45.3 ± 6.3 
6c 100 19.3 ± 3.0 37.9 ± 14.4 19.4 
1000 21.8 ± 6.2 19.1 ± 6.5 85.3f 
Control 14.1 ± 3.7 14.1 ± 3.7 
Estrone 1.5 52.5 ± 6.6 
(-)-6b 100 16.5 ± 2.9 41.6 ± 7.8 28.0 
(+)-6b 100 13.6 ± 3.8 44.0 ± 5.3 21.7 
(-)-6c 100 17.5 ± 3.0 33.6 ± 2.9 49.0e 
(+)-6c 100 16.2 ± 2.2 40.5 ± 8.2 30.9 
a Dose per animal, administered on three consecutive days s.c. 
b Uterus dry weight (mg)/body weight (g) x 100, determined 24 h after the last injection; mean of 10 animals 
± S D 
c Simultaneous administration of 1.5 nmol (0.4 (jug) of estrone/animal and day 
d The r-test according to Student was used 
e Significant at P < 0.05 
f Significant at P < 0.01 
Discussion 
A number of dibenzo[a,g]quinolizin-8-ones were synthesized by reacting substituted 1-
oxoisoquinolines with the respective homophthalic acid anhydride. The methoxy func-
tions were cleaved and converted into acetoxy groups. Essential structural elements for 
high binding affinity for the estrogen receptor are a single acetoxy group in each aromatic 
ring and a short alkyl chain in position 6 of the tetracycle. It could be demonstrated that 
mainly the (—)-enantiomers contribute to the binding affinity. The stereospecificity of 
receptor binding was not unexpected since the binding of steroids is also dependent on 
their steric structure (Wakeling & Bowler, 1988a). Molecular modeling studies showed 
that the substituent in position 6 adopts an axial orientation, such as the methyl group in 
estradiol does. When we studied other tetracyclic systems, we observed that differences 
in receptor binding between enantiomers are not a general feature of this class of 
heterocycles. In the 6-alkyl-indolo[2,l-a]isoquinoline series, both optical isomers dis-
played similar R B A values (Polossek et al., 1992). 
Since the objective of this work has been the development of drugs with a specific 
cytostatic action on estrogen receptor-positive tumors, we compared the effects of the 
dibenzoquinolizinones in two different cell lines. One line (MCF-7) contains estrogen 
receptors and therefore can be considered hormone dependent, the other one ( M D A -
M B 231) lacks them. Derivatives with one acetoxy group in each benzene ring (6a-d) 
strongly inhibited the growth of M C F - 7 cells. A t 1 | J L M , the inhibitory effect was still 50%. 
Comparison of the cytostatic effects in M C F - 7 and M D A - M B 231 breast cancer cells at a 
concentration of 1 x 10~5 M showed that these compounds are preferably active in 
estrogen receptor-positive cells. These data are in accord with the high binding affinity 
for the estrogen receptor. Concerning the specific cytostatic activity of the stereoisomers 
of derivatives 6b and 6c, it was shown that (—)-6b is more active than its (+)-analogue 
due to its higher affinity. For 6c, we were not able to demonstrate a similar difference in 
activity. 
Concerning the endocrine profile of these compounds, we determined their estrogenic 
and antiestrogenic properties in the uterine weight test. Only a very weak stimulation of 
uterine growth was recorded. A l l derivatives with activity in M C F - 7 cells, except 6a, 
exhibited a significant antiestrogenic effect in immature mice at a dose of 1 (xmol/animal. 
Surprisingly, the enantiomers of 6b and 6c did not differ very much in their estrogenic 
activities, despite the marked differences in receptor binding. This is probably due to the 
rather flat course of the uterotrophic dose-response curves observed for this class of 
compounds. In direct comparison, a trend towards higher endocrine activity of the 
stereoisomers which are preferably bound by the estrogen receptor can be recognized. 
The antiuterotrophic effect showed a much stronger dose dependence, therefore differ-
ences in activity are more pronounced. It also has to be taken into account that the R B A 
yalues had been determined with the acetates, whereas the in vivo activities of the 
dibenzoquinolizinones are probably due to the free phenolic compounds which are 
readily formed by esterase-catalyzed hydrolysis (Birnböck et al., 1987). 
Derivatives with antiestrogenic properties in this assay strongly inhibited the growth of 
hormone-sensitive breast cancer cells. This relationship of estrogen antagonism in vivo 
and antiproliferative activity in M C F - 7 breast cancer cells has been well established 
(Wakeling & Bowler, 1988b). The specific mode of action of derivatives 6a-d on 
estrogen receptor-positive mammary tumor cells warrants further experiments to evaluate 
their antineoplastic activity in vivo. 
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